Click
Chat
 
Du kan vedhæfte PDF, JPG, PNG, DOC(X), XLS(X) og TXT-filer. Klik på ikonet, vælg fil og vent til upload er færdig før du indsender eller uploader endnu en fil.
60
Vedhæft Send
Historik

Vælg chat via ovenstående menu
Luk reklame

DANMARKS STØRSTE INVESTORSITE MED DEBAT, CHAT OG NYHEDER

Orphazyme Now Sees Higher Cash Reserves at End of 2021

5/10 07:58


  • (PLX AI) – Orphazyme now expects to end 2021 with a cash position of no less than DKK 80 million, up from about DKK 50 million guided previously.
  • • The improved cash guidance relates to the ongoing restructuring plan, which has enabled the company to deliver more than anticipated savings in headcount and other costs
  • • The company continues to assess different possibilities for obtaining additional funding to sustain operations in the longer-term
  • • Also announces regulatory updates for its investigational drug candidate, arimoclomol, for which it is seeking marketing authorization in both Europe and the United States for the treatment of Niemann-Pick disease Type C (NPC)
  • • Orphazyme now anticipates a CHMP opinion in Q1 2022 compared to previous Q4 2021
  • • Meeting with FDA in mid-October, will update market after